What are the major opportunities in the B-Cell Maturation Antigen (BCMA) Targeted Therapies market? What are the strategies for the B-Cell Maturation Antigen (BCMA) Targeted Therapies market?

For detailed insights on the major opportunities and strategies in the B-Cell Maturation Antigen (BCMA) Targeted Therapies market, Read More

How does the B-Cell Maturation Antigen (BCMA) Targeted Therapies market relate to the overall economy and other similar markets?

For detailed insights on B-Cell Maturation Antigen (BCMA) Targeted Therapies's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the B-Cell Maturation Antigen (BCMA) Targeted Therapies market growth? SWOT analysis of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market.

For detailed insights on the key dynamics influencing the B-Cell Maturation Antigen (BCMA) Targeted Therapies market growth and SWOT analysis of the B-Cell Maturation Antigen (BCMA) Targeted Therapies industry, Read More

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026

Name: B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Product Type (Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies), By Indication Type (Multiple Myeloma, Plasma Cell Leukemia), By End User (Hospitals, Specialty Clinics) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

• B-Cell Maturation Antigen (BCMA) Targeted Therapies market size has reached to $15.09 billion in 2025

• Expected to grow to $44.29 billion in 2030 at a compound annual growth rate (CAGR) of 24%

• Growth Driver: Rising Incidence Of Multiple Myeloma

• Market Trend: Innovations in CAR-T Cell Treatment for Multiple Myeloma

• North America was the largest region in 2025.

What Is Covered Under B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

B-cell maturation antigen (BCMA) targeted therapies refer to a class of treatments designed to specifically target BCMA, a protein expressed on the surface of mature B-cells and plasma cells. BCMA is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in B-cell development, survival, and differentiation into plasma cells. BCMA-targeted therapies represent a significant advancement in the treatment of multiple myeloma, offering effective options for patients with relapsed or refractory disease.

The main types of products for B-cell maturation antigen (BCMA) targeted therapies include antibody-drug conjugates (ADCs), chimeric antigen receptor T (CAR-T) cell therapy, and bispecific antibodies. Antibody drug conjugates (ADCs) are targeted therapies that link a cancer-specific antibody to a cytotoxic drug, enabling precise destruction of cancer cells while minimizing damage to healthy tissue. Main types of indication type are acute lymphoblastic leukemia, and multiple myeloma and used by various end users including hospitals, specialty clinics, and home care settings.

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Global Report 2026 Market Report bar graph

What Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Share 2026?

The b-cell maturation antigen (bcma) targeted therapies market size has grown exponentially in recent years. It will grow from $15.09 billion in 2025 to $18.75 billion in 2026 at a compound annual growth rate (CAGR) of 24.3%. The growth in the historic period can be attributed to improved understanding of bcma biology, increasing multiple myeloma prevalence, early clinical success of bcma-targeted therapies, expansion of hematology oncology centers, rising investment in immuno-oncology research.

What Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Forecast?

The b-cell maturation antigen (bcma) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $44.29 billion in 2030 at a compound annual growth rate (CAGR) of 24.0%. The growth in the forecast period can be attributed to increasing approvals of next-generation bcma therapies, rising demand for off-the-shelf immunotherapies, expansion of combination treatment strategies, growing focus on durable remission outcomes, increasing use of ai-driven patient stratification. Major trends in the forecast period include increasing adoption of car-t cell therapies, rising development of bispecific antibody platforms, growing use of bcma-targeted adcs, expansion of personalized immunotherapy regimens, enhanced focus on relapsed and refractory myeloma care.

Book your 30 minutes free consultation with our research experts

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segmentation

1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies

2) By Indication Type: Multiple Myeloma, Plasma Cell Leukemia

3) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs

2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells

3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies

What Is The Driver Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

The rising incidence of multiple myeloma is expected to propel the growth of the b-cell maturation antigen (BCMA) targeted therapies market going forward. Multiple myeloma is a type of cancer that primarily affects plasma cells, which are a crucial component of the immune system responsible for producing antibodies. The increasing incidence of multiple myeloma is attributed to several factors, including an aging global population, improved diagnostic capabilities, and variations in healthcare access. B-cell maturation antigen (BCMA) targeted therapies are crucial in treating multiple myeloma by targeting and eliminating malignant plasma cells that express BCMA, offering a promising approach for more effective and targeted treatment. For instance, in August 2024, according to the American Cancer Society, a US-based professional organization, in 2024, approximately 35,780 new cases of multiple myeloma were diagnosed in the United States, with 19,520 cases in men and 16,260 cases in women. Additionally, about 12,540 deaths are anticipated, including 7,020 in men and 5,520 in women. Therefore, the rising incidence of multiple myeloma is driving growth in the b-cell maturation antigen (BCMA) targeted therapies industry.

Key Players In The Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

Major companies operating in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends and Insights

Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are focusing on developing innovative treatments such as CAR-T cell therapy to enhance the efficacy and precision of targeting cancer cells. CAR-T cell therapy is a type of immunotherapy that involves modifying a patient's T cells to express chimeric antigen receptors (CARs) to target and kill cancer cells. For instance, in April 2024, Johnson & Johnson, a US-based pharmaceutical industry company, received U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy for treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy and are refractory to lenalidomide.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical industry company, acquired Gracell Biotechnologies Inc. for approximately $1.2 billion. With this acquisition, AstraZeneca aims to enhance its cell therapy portfolio by integrating Gracell's FasTCAR-enabled GC012F therapy, targeting cancer and autoimmune diseases, to address significant unmet medical needs. Gracell Biotechnologies Inc. is a China-based biotechnology company specializing in developing B-cell maturation antigen (BCMA) therapies for multiple myeloma and B-cell malignancies.

Regional Outlook

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

The B-cell maturation antigen (BCMA) targeted therapies market consists of revenues earned by entities by providing services such as research and development services, clinical trials management, manufacturing and production services, regulatory consulting and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The B-cell maturation antigen (BCMA) targeted therapies market also includes sales of antibody-drug conjugates (ADCs), BCMA-targeted immunotherapies, and gene therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026?

The b-cell maturation antigen (bcma) targeted therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the b-cell maturation antigen (bcma) targeted therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$18.75 billion
Revenue Forecast In 2035	$44.29 billion
Growth Rate	CAGR of 24.3% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Product Type, Indication Type, End User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Industry 4.0 & Intelligent Manufacturing

4.1.4 Digitalization, Cloud, Big Data & Cybersecurity

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Increasing Adoption Of Car-T Cell Therapies

4.2.2 Rising Development Of Bispecific Antibody Platforms

4.2.3 Growing Use Of Bcma-Targeted Adcs

4.2.4 Expansion Of Personalized Immunotherapy Regimens

4.2.5 Enhanced Focus On Relapsed And Refractory Myeloma Care

5. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Oncology Clinics

5.3 Hematology Centers

5.4 Academic Medical Centers

5.5 Cell Therapy Treatment Centers

6. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, Comparisons And Growth Rate Analysis

7.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segmentation

9.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies

9.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Multiple Myeloma, Plasma Cell Leukemia

9.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Specialty Clinics

9.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs

9.5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells

9.6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies

10. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Regional And Country Analysis

10.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

11.1. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

12.1. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

13.1. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

14.1. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

14.2. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

15.1. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

16.1. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

17.1. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

17.2. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

18.1. Taiwan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

18.2. Taiwan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

19.1. South East Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

19.2. South East Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

20.1. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

20.2. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

21.1. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

22.1. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

23.1. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

24.1. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

25.1. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

26.1. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

26.2. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

27.1. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

28.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

28.2. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

29.1. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

29.2. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

30.1. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

30.2. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

31.1. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

31.2. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

32.1. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

33.1. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

33.2. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

34.1. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

34.2. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Segmentation By Indication Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Regulatory and Investment Landscape

36. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Landscape And Company Profiles

36.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Company Profiles

36.3.1. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Novartis Overview, Products and Services, Strategy and Financial Analysis

36.3.3. GlaxoSmithKline Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis

37. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Other Major And Innovative Companies

Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche

38. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

40. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market High Potential Countries, Segments and Strategies

40.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2030 - Countries Offering Most New Opportunities

40.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2030 - Segments Offering Most New Opportunities

40.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Overview Of Key Products - Product Examples

Table 2: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Attractiveness, Factor-Wise Evaluation

Table 3: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Supply Chain Analysis

Table 4: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Raw Material Providers

Table 5: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Resource Providers

Table 6: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Manufacturers (Suppliers)

Table 7: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Distributors And Channel Partners

Table 8: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Key Technologies & Future Trends

Table 9: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Trends

Table 10: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major End Users

Table 11: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Growth, 2020-2025, $ Billion

Table 13: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - TAM, US$ Billion, 2025

Table 15: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: Taiwan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Taiwan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: South East Asia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: South East Asia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 96: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Company Scoring Matrix

Table 97: Bristol Myers Squibb Company Financial Performance

Table 98: Novartis Financial Performance

Table 99: GlaxoSmithKline Financial Performance

Table 100: Takeda Pharmaceutical Company Limited Financial Performance

Table 101: Amgen Inc Financial Performance

Table 102: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Competitive Benchmarking (In USD Billions)

Table 103: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Competitive Dashboard

Table 104: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 105: Global, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Gain ($ Billion), Segmentation By Product Type, 2025 – 2030

Table 106: Global, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Gain ($ Billion), Segmentation By Indication Type, 2025 – 2030

Table 107: Global, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

List Of Figures

Figure 1: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Overview Of Key Products - Product Examples

Figure 2: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Supply Chain Analysis

Figure 4: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Raw Material Providers

Figure 5: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Resource Providers

Figure 6: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Manufacturers (Suppliers)

Figure 7: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Distributors And Channel Partners

Figure 8: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Key Technologies & Future Trends

Figure 9: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major Trends

Figure 10: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Major End Users

Figure 11: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - TAM, US$ Billion, 2025

Figure 15: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: Taiwan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Taiwan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: South East Asia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: South East Asia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 96: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Company Scoring Matrix

Figure 97: Bristol Myers Squibb Company Financial Performance

Figure 98: Novartis Financial Performance

Figure 99: GlaxoSmithKline Financial Performance

Figure 100: Takeda Pharmaceutical Company Limited Financial Performance

Figure 101: Amgen Inc Financial Performance

Figure 102: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Competitive Benchmarking (In USD Billions)

Figure 103: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Competitive Dashboard

Figure 104: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 105: Global, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Gain ($ Billion), Segmentation By Product Type, 2025 – 2030

Figure 106: Global, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Gain ($ Billion), Segmentation By Indication Type, 2025 – 2030

Figure 107: Global, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Next-Generation Antibody Therapeutics Market Report 2026 - Global Outlook – By Types Of Antibodies (Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types), By Therapeu...

Diffuse Large B-cell Lymphoma Therapeutics Market Report 2026 - Global Outlook – By Drug Class (Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs), By Therapy (Targeted Therapy, Imm...

Preventive Vaccines Market Report 2026 - Global Outlook – By Type (Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines), By ...

Therapeutic BCG Vaccines Market Report 2026 - Global Outlook – By Type (Therapy BCG, Other Types), By Demographics (Pediatrics, Adults), By End Use (Hospitals, Clinics, Other End Users) – Market Size, Trends, Strategies,...

Targeted Therapy Market Report 2026 - Global Outlook – By Type (Small Molecule Medicines, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies ), By Application (Brea...

Swine Vaccines Market Report 2026 - Global Outlook – By Product (Attenuated Live Vaccines, Inactivated Vaccines, Subunit Vaccines, Deoxyribonucleic Acid (DNA) Vaccines, Recombinant Vaccines), By Disease (Viral Infections...

Dendritic Cell Cancer Vaccine Market Report 2026 - Global Outlook – By Product (CreaVax, Sipuleucel-T (Provenge), Other Products), By Distribution Channel (Hospitals, Cancer Centers, Ambulatory Surgical Centers, Clinics)...

Frequently Asked Questions

How big is the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

The B-Cell Maturation Antigen (BCMA) Targeted Therapies market was valued at $15.09 billion in 2025, increased to $18.75 billion in 2026, and is projected to reach $44.29 billion by 2030.

What is the B-Cell Maturation Antigen (BCMA) Targeted Therapies market growth?

The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market is expected to grow at a CAGR of 24.0% from 2026 to 2035 to reach $44.29 billion by 2035.

Who are the key players in B-Cell Maturation Antigen (BCMA) Targeted Therapies market?

Some Key Players in the B-Cell Maturation Antigen (BCMA) Targeted Therapies market Include, Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences .

What is the anticipated growth trend for the B-Cell Maturation Antigen (BCMA) Targeted Therapies market?

Major trend in this market includes: Innovations in CAR-T Cell Treatment for Multiple Myeloma. For further insights on this market. request a sample here

Which region has the most growth potential in the B-Cell Maturation Antigen (BCMA) Targeted Therapies market?

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2025. The regions covered in the b-cell maturation antigen (bcma) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.